A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy
- 11 February 2010
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 21 (9) , 1779-1785
Abstract
Background: This retrospective study was carried out to evaluate the prognostic significance of clinical factors in patients treated for metastatic gastric cancer with second-line chemotherapy. Patients and methods: We evaluated the prognostic significance of various clinical factors in 126 patients, who were treated with second-line chemotherapy. Results: Median progression-free and overall survival (OS) for second-line chemotherapy were 3.3 and 5.3 months, respectively, with an overall response rate of 11.1%. Multivariate analysis identified three independent prognostic factors: performance status: Eastern Cooperative Oncology Group zero to one [hazard ratio (HR) 2.3, 95% confidence interval (CI) 1.7–5.4], hemoglobin (Hb) level: ≥10 g/dl (HR 2.2, 95% CI 2.1–2.4) and time-to-progression (TTP) under first-line therapy: ≥5 months (HR 0.5, 95% CI 0.3–0.8). From the obtained data, a prognostic index was constructed, dividing the patients into three risk groups: good (n = 40), intermediate (n = 36) and poor risk group (n = 56). The median survival for good, intermediate and poor risk groups were 13.5, 6.0 and 2.9 months, respectively, whereas the 1-year OS rates were 50.2%, 14.2% and 2.6%, respectively (P = 0.00001). Conclusions: With inadequate data from randomized controlled trials at the moment, our report indicates that second-line chemotherapy is effective and beneficial in patients with good performance status, higher Hb level along with higher TTP under first-line therapy.Keywords
This publication has 22 references indexed in Scilit:
- Gastric cancerCritical Reviews in Oncology/Hematology, 2009
- A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancerBMC Cancer, 2009
- Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?British Journal of Cancer, 2008
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 studyThe Lancet Oncology, 2007
- Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinomaAnnals of Oncology, 2007
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study GroupJournal of Clinical Oncology, 2006
- Second-Line Chemotherapy of Advanced Disseminated Gastric Cancer after Cisplatin, Infusional 5-Fluorouracil, Folinic Acid (PLF): Benefit Dependant on Progression-Free Interval after First-Line TherapyOncology Research and Treatment, 2005
- Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient DataJournal of Clinical Oncology, 2004
- Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?European Journal of Cancer, 1998